2006, Number 2
<< Back Next >>
Rev Salud Publica Nutr 2006; 7 (2)
Acción inhibitoria de probióticos sobre el crecimiento axénico in vitro de entamoeba histolytica
Barrón-González MP, Serrano-Vázquez GC, Villarreal-Treviño L, Mata-Cárdenas BD, Verduzco-Martínez JA, Morales-Vallarta MR
Language: Spanish
References: 94
Page:
PDF size: 265.23 Kb.
ABSTRACT
Entamoeba histolytica is the cosmopolitan parasitic protozoo causal agent of amoebiasis and is clinical manifestations, this is most frecuent in the undevelopment contries, were the conditions of sanity are deficient. In Mexico the amoebiasis for Entamoeba histolytica is an important problem in the healt for the frecuency, morbility and mortality. For the control of amebiasis and is clinical manifestations the best drug is the metronidazol but this present secondari effect in patients and effects carcinogenics and mutagenics in mouses, meanwhile new reports present evidences of resistence for this drug. Recent researchs whit probiotics reports the use of probiotics in the treatment of specific diseases has evolved into an extremely valuable option yet to be optimally used in clinical medicine. Probiotics have been shown to have immunomodulating, bioterapeutics, bioprofilactics properties and enhance the mucosal barrier and various uses in diarrhea. In this work the hipotesis is the follow: Is possible the inhibition of grown of Entamoeba histolytica employed conditionated media with probiotics (CMP). In this work we evaluated the efect of 1,10,20 y 100 mg/mL of CMP of the lactic acid bacteria (BAL) considerated alike probiotics
Lactococcus lactis, Lactobacillus casei and
Lactobacillus acidophilus in the axenic grown in vitro of Entamoeba histolytica meanwhile kinetic´s grown, each one was repeated tree time. The results obtained in this asays has been significant diference (ANOVA p=0.05) in the inhibition of grown of
E. histolytica in axenic culture
in vitro. This results pressent an alternative for the control of amebiasis and is clinical manifestations, this nutritional altetnative is bassed in the secondari metabolites produced for the probiotics and this no pressent secondari effects undeseables .
REFERENCES
1.-World Healt Organization. 1997. Amoebiasis-an expert consultation. Weekly Epidemiological Rec. Apr.4; 72(14):97-99.
2.-Lynch, E.C., M.I. Rosenberg and C. Gitler. 1982. An ion chanel forming protein produced by E. histolytica. EMBO. J. 1:801-804
3.-Campos, G.E. 1996. Incremento de la síntesis de quitina en quistes de Entamoeba histolytica por efecto de Mg2+, Mn2+, y Co 2+. Tesis de Postgrado Nivel Maestría de la Facultad de Ciencias Biológicas, UANL.
4.-Legator, M.S., T.H. Connor and M. Stoeckel. 1975. Detection of mutagenic activity of metronidazole and niridazole in body fluids of human and mice. Science. 188:1118-1119.
5.-Samarawickream, N.A., D.M. Brown, J.A. Upcroft, N. Thammapalerd and P. Upcroft. 1997. Involvement of superoxide dismutase and pyruvate: ferredoxin oxidoreductase in mechanisms of metronidazole resistance in Entamoeba histolytica. J. Antimicrob. Hemother. 40:833-840.
6.-Fariborz, M.G., D. Najaf, Y. Kamyar and S. Afshin. 2003. Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World J. Gastroenterol. Aug; 9 (8):1832-1833.
7.-Mombelli, B. and M. Gismondo. 2000. The use of probiotics in medical practice. Int. Antimicrob. Agents.16 (4) 531-536.
8.-Mc Farland, L.V. 2000. Benefical microbes. Health or hazard?. Eur. Gastroenterol Hepatol, 12 (10) 1069-1071.
9.-Penna, F.J. 1989. Diarrea y Probióticos. Simposio sobre utilidad de los probióticos en el manejo de las diarreas. Revista de enfermedades infecciosas en pediatría. Vol X1, número 6, p 182.
10.-Saxelin, M. 1997. Lactobacillus gg: A human probiotic strain with thorough clinical documentation. Food Rev. Int. 13(2): 293-313.
11.-Tannock, G.W. 1997. Properties of lactic-acid bacteria: Plenty of scope for fundamental research. TBITECH. 15:270-274.
12.-Salminen, S., M. Deighton and S. Gorbach. 1993. Lactic acid bacteria in health and disease. In: Lactic acid bacteria (S. Salminen and von Wright, eds.), Marcel Decker, Inc. New York. Pp.199-225.
13.-Saloff-Coste, C.J. 1997. Beneficios de las leches fermentadas y de los probióticos sobre la salud: una revisión, Danone World Newsletter. 15: 1-11.
14.-González, S., G. Ibarracin, R. Locascio, M. Pesce, M. Male, M.C. Apella, R. Pesce, A. Holgado and G. Oliver. 1990. Prevention of infantile diarrhoea by fermented milk. microbiologie aliments nutrition. 8 (4) 349-354.
15.-Salminen, S., et al., Op. cit.
16.-Portier, A., N.P. Boyaka, F. Bougoudogo, M. Dubarry, I. Huneau, D. Tomé, A. Dodin and M. Coste. 1993. Fermented milks and increased antibody responses against cholera in mice. Int J. Immunother. 9:217-224.
17.-Reid, G. 2000. Probiotics in the treatment of diarrheal diseases. Curr. Infect. Dis. Res. 2 (1):78.
18.-Link-Amster, H., F. Rochat, K.Y. Saudan, O. Mignot and J.M. Aeschlimann. 1994. Modulation of a specific humoral immune response and changes in intestial flora mediated through fermented milk intake. Fems. Immun. Med. Microbiol.10:55-64.
19.-Robinson, R.K. and A. Samona. 1992. Healt aspects of bifidus products: a review. Int. J. Food. Sci. Nutr, 43:175-180.
20.-Perez, P.F., J. Minnard, M. Rouvet, C.H. Knabenhans, D. Brassart, G.L. De Antoni and E.J. Shiffrin. 2001. Inhibition of Giardia intestinalis by acellular factors from Lactobacilli: an in vitro study. Appl. Environ. Microbiol. 67:5037-5042.
21.-De Man, J.C., M. Rogosa and T. Shapre. 1960. A medium for the cultivation of lactobacilli. J. Appl.
22.- Diamond, L.S. 1968. Techniques of axenic cultivation of Entamoeba histolytica Schaudinn. 1903 and E. histolytica-like amebae. J. Parasitol 54:1047-1056
23.-Saíd-Fernández, S., J. Vargas-Villegas, J. Castro-Garza, B.D. Mata-Cárdenas, L. Navarro- Marmolejo, G. Lozano-Garza and H. Martínez-Rodríguez. 1988. PEHPS medium: an alternative for axenic cultivation of E.histolytica and E. invadens. Trans.R.Soc.Trop Med. Hyg 82:249-253.
24.-Mata-Cárdenas, B.D., M. R. Morales-Vallarta, J. Vargas-Villegas and S. Saíd-Fernández. 1996. PACSR: A Serum Repleacement for axenic cultivation of Entamoeba histolytica. Trans. Roys. Soc. Trop. Med. Hyg. 90:586.
25.-De Waard, R., J. Garssen, G. Bokken and J.G. Vos. 2002. Antagonistic activity of Lactobacillus casei strain shirota against gastrointestinal Listeria monocitógenes infection in rats. Int. J. Food Microbiol. 73:93-100.
26.-Glück, U. and G. Jan-Olaf. 2003. Ingested probiotics reduce nasal colonization with pathogenic bacteria (Staphylococcus aureus, Streptococcus pneumoniae, and Beta-hemolytic streptococci). Am. J. Clinical Nutrition. 77:517-520.
27.-Sgouras, D., P. Maragkoudakis, K. Petraki, B. Martínez-González, E. Michopoulos, G. Kalantzopoulos, E. Tsakalidou and A. Mentis. 2004. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl. Environ Microbiol. 70 :518-526.
28.-Fariborz, M.G., et al, Op. Cit.
29.-Perez, P.F., et al, Op. Cit.
31.-Samarawickream, N.A., et al, Op. Cit.
World Healt Organization. 1997. Amoebiasis-an expert consultation. Weekly Epidemiological Rec. Apr.4; 72(14):97-99.
Lynch, E.C., M.I. Rosenberg and C. Gitler. 1982. An ion chanel forming protein produced by E. histolytica. EMBO. J. 1:801-804
Campos, G.E. 1996. Incremento de la síntesis de quitina en quistes de Entamoeba histolytica por efecto de Mg2+, Mn2+, y Co2+. Tesis de Postgrado Nivel Maestría de la Facultad de Ciencias Biológicas, UANL.
Legator, M.S., T.H. Connor and M. Stoeckel. 1975. Detection of mutagenic activity of metronidazole and niridazole in body fluids of human and mice. Science. 188:1118-1119.
Samarawickream, N.A., D.M. Brown, J.A. Upcroft, N. Thammapalerd and P. Upcroft. 1997. Involvement of superoxide dismutase and pyruvate: ferredoxin oxidoreductase in mechanisms of metronidazole resistance in Entamoeba histolytica. J. Antimicrob. Hemother. 40:833-840.
Fariborz, M.G., D. Najaf, Y. Kamyar and S. Afshin. 2003. Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World J. Gastroenterol. Aug; 9(8):1832-1833.
Mombelli, B. and M. Gismondo. 2000. The use of probiotics in medical practice. Int. Antimicrob. Agents.16 (4) 531-536.
Mc Farland, L.V. 2000. Benefical microbes. Health or hazard?. Eur. Gastroenterol Hepatol, 12(10) 1069-1071.
Penna, F.J. 1989. Diarrea y Probióticos. Simposio sobre utilidad de los probióticos en el manejo de las diarreas. Revista de enfermedades infecciosas en pediatría. Vol X1, número 6, p 182.
Saxelin, M. 1997. Lactobacillus gg: A human probiotic strain with thorough clinical documentation. Food Rev. Int. 13(2): 293-313.
Tannock, G.W. 1997. Properties of lactic-acid bacteria: Plenty of scope for fundamental research. TBITECH. 15:270-274.
Salminen, S., M. Deighton and S. Gorbach. 1993. Lactic acid bacteria in health and disease. In: Lactic acid bacteria (S. Salminen and von Wright, eds.), Marcel Decker, Inc. New York. Pp.199-225.
Saloff-Coste, C.J. 1997. Beneficios de las leches fermentadas y de los probióticos sobre la salud: una revisión, Danone World Newsletter. 15: 1-11.
González, S., G. Ibarracin, R. Locascio, M. Pesce, M. Male, M.C. Apella, R. Pesce, A. Holgado and G. Oliver. 1990. Prevention of infantile diarrhoea by fermented milk. microbiologie aliments nutrition. 8(4) 349-354.
Salminen, S., et al., Op. cit.
Portier, A., N.P. Boyaka, F. Bougoudogo, M. Dubarry, I. Huneau, D. Tomé, A. Dodin and M. Coste. 1993. Fermented milks and increased antibody responses against cholera in mice. Int J. Immunother. 9:217-224.
Reid, G. 2000. Probiotics in the treatment of diarrheal diseases. Curr. Infect. Dis. Res. 2 (1):78.
Link-Amster, H., F. Rochat, K.Y. Saudan, O. Mignot and J.M. Aeschlimann. 1994. Modulation of a specific humoral immune response and changes in intestial flora mediated through fermented milk intake. Fems. Immun. Med. Microbiol.10:55-64.
Robinson, R.K. and A. Samona. 1992. Healt aspects of bifidus products: a review. Int. J. Food. Sci. Nutr, 43:175-180.
Perez, P.F., J. Minnard, M. Rouvet, C.H. Knabenhans, D. Brassart, G.L. De Antoni and E.J. Shiffrin. 2001. Inhibition of Giardia intestinalis by acellular factors from Lactobacilli: an in vitro study. Appl. Environ. Microbiol. 67:5037-5042.
De Man, J.C., M. Rogosa and T. Shapre. 1960. A medium for the cultivation of lactobacilli. J. Appl. Bacteriol. 23:130-135.
Diamond, L.S. 1968. Techniques of axenic cultivation of Entamoeba histolytica Schaudinn. 1903 and E. histolytica-like amebae. J. Parasitol 54:1047-1056
Saíd-Fernández, S., J. Vargas-Villegas, J. Castro-Garza, B.D. Mata-Cárdenas, L. Navarro-Marmolejo, G. Lozano-Garza and H. Martínez-Rodríguez. 1988. PEHPS medium: an alternative for axenic cultivation of E.histolytica and E. invadens. Trans.R.Soc.Trop Med. Hyg 82:249-253.
Mata-Cárdenas, B.D., M. R. Morales-Vallarta, J. Vargas-Villegas and S. Saíd-Fernández. 1996. PACSR: A Serum Repleacement for axenic cultivation of Entamoeba histolytica. Trans. Roys. Soc. Trop. Med. Hyg. 90:586.
De Waard, R., J. Garssen, G. Bokken and J.G. Vos. 2002. Antagonistic activity of Lactobacillus casei strain shirota against gastrointestinal Listeria monocitógenes infection in rats. Int. J. Food Microbiol. 73:93-100.
Glück, U. and G. Jan-Olaf. 2003. Ingested probiotics reduce nasal colonization with pathogenic bacteria (Staphylococcus aureus, Streptococcus pneumoniae, and Beta-hemolytic streptococci). Am. J. Clinical Nutrition. 77:517-520.
Sgouras, D., P. Maragkoudakis, K. Petraki, B. Martínez-González, E. Michopoulos, G. Kalantzopoulos, E. Tsakalidou and A. Mentis. 2004. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl. Environ Microbiol. 70 :518-526.
Fariborz, M.G., et al, Op. Cit.
Perez, P.F., et al, Op. Cit.
Samarawickream, N.A., et al, Op. Cit.
Full text